News All News

New findings by Harvard stem cell biologists suggest it may be possible in the future to regrow wounded skin without scarring.

Researchers in Andrew Kruse’s lab overcame a key obstacle in using the hormone relaxin as a therapy for heart disease. With support from Harvard’s Blavatnik Biomedical Accelerator, this discovery led to the launch of Tectonic Therapeutic, which is now testing its relaxin-based drug in clinical trials.

New research out of Harvard Medical School suggests that lithium deficiency may be a key driver of Alzheimer’s disease and a promising target for early diagnosis and treatment. Harvard’s Office of Technology Development has protected the innovations related to this research and is actively seeking industry partners for commercialization to advance these discoveries.

With funding and business development support from the Blavatnik Biomedical Accelerator, a research team’s lab discovery propelled to startup success.